Maria Elena Lunati
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maria Elena Lunati has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Laura Montefusco
Division of Endocrinology, ASST Fatebenefratelli Sacco , 20157 Milan
3 shared publications - Paolo Fiorina
International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, DIBIC, Università di Milano, Milan, Italy
3 shared publications - Ida Pastore
International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, DIBIC, Università degli Studi di Milano , 20157 Milan
2 shared publications Alessandra Gandolfi
Division of Endocrinology, ASST Fatebenefratelli-Sacco , 20121 Milan
1 shared publication- Alessandra Gandolfi
Division of Endocrinology, ASST Fatebenefratelli-Sacco, Milan, Italy
1 shared publication Antonio Rossi
Department of Biomedical and Clinical Sciences, University of Milan , 20157 Milan
1 shared publication
Latest Publications
- Open Access
- 23 February 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (7) , 1842-1849
The use of semaglutide as an add-on therapy in patients with latent autoimmune diabetes in adults
Introduction: Semaglutide, a GLP-1R agonist (GLP-1RA), has demonstrated high efficacy in the management of type 2 diabetes. Few data in literature are available regarding the use of this agent in patients affected by latent autoimmune diabetes in adults (LADA). The purpose of this study is to analyze the efficacy of semaglutide use in patients affected by LADA. Materials and methods: In this retrospective study, we collected and analyzed data of 80 patients with LADA treated with semaglutide, either oral or subcutaneous, as an add-on therapy to insulin. Laboratory and clinical parameters and metrics from continuous glucose monitoring were collected where available. Results: Among 80 patients, 68 continued semaglutide (57/68 oral and 11/68 subcutaneous) for at least 6 months, whereas 12/80 patients discontinued treatment. After 6 months, semaglutide users showed statistically significant reduction in glycated hemoglobin, body mass index, and insulin total daily dose. Interestingly, serum C-peptide levels and the time-in-range values increased, without changes in the time below range. Subjects with residual β-cell function showed a higher body mass index and insulin total daily dose reduction. Moreover, the subgroup of subjects with preserved β-cell mass showed a greater improvement in time in range as compared to those with poor C-peptide production. Finally, 14/68 subjects suspended insulin bolus administration after starting semaglutide. Conclusion: Semaglutide as an add-on treatment to insulin exerted relevant clinical beneficial effects on the glycometabolic control in patients with LADA. These effects are enhanced in those patients with preserved β-cell function.
- 23 February 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (7) , 1842-1849
Open AccessThe use of semaglutide as an add-on therapy in patients with latent autoimmune diabetes in adults
Introduction: Semaglutide, a GLP-1R agonist (GLP-1RA), has demonstrated high efficacy in the management of type 2 diabetes. Few data in literature are available regarding the use of this agent in patients affected by latent autoimmune diabetes in adults (LADA). The purpose of this study is to analyze the efficacy of semaglutide use in patients affected by LADA. Materials and methods: In this retrospective study, we collected and analyzed data of 80 patients with LADA treated with semaglutide, either oral or subcutaneous, as an add-on therapy to insulin. Laboratory and clinical parameters and metrics from continuous glucose monitoring were collected where available. Results: Among 80 patients, 68 continued semaglutide (57/68 oral and 11/68 subcutaneous) for at least 6 months, whereas 12/80 patients discontinued treatment. After 6 months, semaglutide users showed statistically significant reduction in glycated hemoglobin, body mass index, and insulin total daily dose. Interestingly, serum C-peptide levels and the time-in-range values increased, without changes in the time below range. Subjects with residual β-cell function showed a higher body mass index and insulin total daily dose reduction. Moreover, the subgroup of subjects with preserved β-cell mass showed a greater improvement in time in range as compared to those with poor C-peptide production. Finally, 14/68 subjects suspended insulin bolus administration after starting semaglutide. Conclusion: Semaglutide as an add-on treatment to insulin exerted relevant clinical beneficial effects on the glycometabolic control in patients with LADA. These effects are enhanced in those patients with preserved β-cell function.
- 9 September 2024
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 23 (2) , 2201-2205
A new glucose monitoring system for the intermittent monitoring of interstitial glucose values in patients with diabetes mellitus
Objectives Glucose monitoring in diabetes is changing overtime with a constant development of new devices for continuous glucose monitoring (CGM). Aim of this observational, prospective study was to evaluate the clinical performance of a novel intermittently scanned CGM system, the Glunovo Flash in a cohort of patients with type 1 diabetes. Methods A total of 45 patients with T1D followed at the Endocrinology Unit of the ASST-FBF-Sacco (Milan) were enrolled. All patients were habitual CGM users and were asked to wear simultaneously the Glunovo Flash system and their habitual CGM device for 14 days. A comparison of CGM glucose metrics was performed. Patients’ opinions on the new device were also collected. Results Thirty-five patients completed the study period of two weeks (7 habitual real time CGM users, 28 habitual intermittently scanned CGM users). Mean Time In Range resulted significantly higher with the novel studied sensor respect to intermittently scanned CGM comparator. No differences were found considering other glucose metrics. A positive correlation was found between the Time In Range recorded by Glunovo Flash and intermittently scanned CGM comparators as well as for Time Above Range, Glucose Management Indicator, Time Below Range and Coefficient of Variation. No correlations were found between glucose metrics recorded by Glunovo Flash and real time CGM comparators. Patients reported a positive experience of use with the new sensor but some elements appeared improvable. Conclusions The CGM device Glunovo Flash for patients with diabetes shows similar performance to other intermittently scanned CGM systems.
- 9 September 2024
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 23 (2) , 2201-2205
A new glucose monitoring system for the intermittent monitoring of interstitial glucose values in patients with diabetes mellitus
Objectives Glucose monitoring in diabetes is changing overtime with a constant development of new devices for continuous glucose monitoring (CGM). Aim of this observational, prospective study was to evaluate the clinical performance of a novel intermittently scanned CGM system, the Glunovo Flash in a cohort of patients with type 1 diabetes. Methods A total of 45 patients with T1D followed at the Endocrinology Unit of the ASST-FBF-Sacco (Milan) were enrolled. All patients were habitual CGM users and were asked to wear simultaneously the Glunovo Flash system and their habitual CGM device for 14 days. A comparison of CGM glucose metrics was performed. Patients’ opinions on the new device were also collected. Results Thirty-five patients completed the study period of two weeks (7 habitual real time CGM users, 28 habitual intermittently scanned CGM users). Mean Time In Range resulted significantly higher with the novel studied sensor respect to intermittently scanned CGM comparator. No differences were found considering other glucose metrics. A positive correlation was found between the Time In Range recorded by Glunovo Flash and intermittently scanned CGM comparators as well as for Time Above Range, Glucose Management Indicator, Time Below Range and Coefficient of Variation. No correlations were found between glucose metrics recorded by Glunovo Flash and real time CGM comparators. Patients reported a positive experience of use with the new sensor but some elements appeared improvable. Conclusions The CGM device Glunovo Flash for patients with diabetes shows similar performance to other intermittently scanned CGM systems.
- 3 August 2023
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 46 (12) , 2445-2452
The anti-inflammatory and immunological properties of SGLT-2 inhibitors
Background Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) are antidiabetic oral drugs that act on proximal renal tubules promoting renal glucose excretion. Although SGLT-2i belong to the class of hypoglycemic agents, in the last years great interest has emerged in studying their pleiotropic effects, beyond their ability to lower glucose levels. Purpose In this review we are describing the anti-inflammatory and immunological properties of SGLT-2i; furthermore, we are addressing how the mechanisms associated with the aforementioned anti-inflammatory properties may contribute to the beneficial effects of SGLT-2i in diabetes. Methods A systematic search was undertaken for studies related the properties of SGLT-2i in reducing the inflammatory milieu of acute and chronic disease by acting on the immune system, independently by glycemia. Results Recently, some data described the anti-inflammatory and immunological properties of SGLT-2 in both pre-clinical and clinical studies. Numerous data confirmed the cardio- and -renal protective effects of SGLT-2i in patients with heart failure and kidney diseases, with or without diabetes. Conclusions SGLT-2i are promising drugs with anti-inflammatory and immunological properties. Despite the mechanism of action of SGLT-2i is not fully understood, these drugs demonstrated anti-inflammatory effects, which may help in keeping under control the variety of complications associated with diabetes.
- 3 August 2023
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 46 (12) , 2445-2452
The anti-inflammatory and immunological properties of SGLT-2 inhibitors
Background Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) are antidiabetic oral drugs that act on proximal renal tubules promoting renal glucose excretion. Although SGLT-2i belong to the class of hypoglycemic agents, in the last years great interest has emerged in studying their pleiotropic effects, beyond their ability to lower glucose levels. Purpose In this review we are describing the anti-inflammatory and immunological properties of SGLT-2i; furthermore, we are addressing how the mechanisms associated with the aforementioned anti-inflammatory properties may contribute to the beneficial effects of SGLT-2i in diabetes. Methods A systematic search was undertaken for studies related the properties of SGLT-2i in reducing the inflammatory milieu of acute and chronic disease by acting on the immune system, independently by glycemia. Results Recently, some data described the anti-inflammatory and immunological properties of SGLT-2 in both pre-clinical and clinical studies. Numerous data confirmed the cardio- and -renal protective effects of SGLT-2i in patients with heart failure and kidney diseases, with or without diabetes. Conclusions SGLT-2i are promising drugs with anti-inflammatory and immunological properties. Despite the mechanism of action of SGLT-2i is not fully understood, these drugs demonstrated anti-inflammatory effects, which may help in keeping under control the variety of complications associated with diabetes.